Genmab Total Liabilities 2010-2024 | GNMSF

Genmab total liabilities for the quarter ending December 31, 2024 were $1.322B, a 147.39% increase year-over-year.

  • Genmab total liabilities for 2024 were $1.322B, a 147.39% increase from 2023.
  • Genmab total liabilities for 2023 were $0.534B, a 32.98% increase from 2022.
  • Genmab total liabilities for 2022 were $0.402B, a 3.86% increase from 2021.

Genmab Total Liabilities 2010-2024 | GNMSF

  • Genmab total liabilities for 2024 were $1.322B, a 147.39% increase from 2023.
  • Genmab total liabilities for 2023 were $0.534B, a 32.98% increase from 2022.
  • Genmab total liabilities for 2022 were $0.402B, a 3.86% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.2B
Amgen (AMGN)$156.5B
Gilead Sciences (GILD)$129.7B
Vertex Pharmaceuticals (VRTX)$117.9B
Bristol Myers Squibb (BMY)$109.4B
CSL (CSLLY)$78.2B
GSK (GSK)$75B
Regeneron Pharmaceuticals (REGN)$73.6B
Argenex SE (ARGX)$38.9B
Alnylam Pharmaceuticals (ALNY)$33.2B
BioNTech SE (BNTX)$28.7B
BeiGene (ONC)$22.6B
Biogen (BIIB)$20.1B
Illumina (ILMN)$15.9B
Insmed (INSM)$14.2B
Genmab (GMAB)$14.1B
Incyte (INCY)$13.6B
Intra-Cellular Therapies (ITCI)$13.6B
Moderna (MRNA)$12.7B
BioMarin Pharmaceutical (BMRN)$12.4B
Swedish Orphan Biovitrum (BIOVF)$10.9B
Vaxcyte (PCVX)$10.5B
Bio-Techne Corp (TECH)$10.4B
Sarepta Therapeutics (SRPT)$10.3B
Exelixis (EXEL)$9.8B
Exact Sciences (EXAS)$9.1B
QIAGEN (QGEN)$8.8B
Ascendis Pharma (ASND)$8.7B
Bio-Rad Laboratories (BIO.B)$8.7B
Repligen (RGEN)$8.2B